Q

Quantum BioPharma Ltd
CNSX:QNTM

Watchlist Manager
Quantum BioPharma Ltd
CNSX:QNTM
Watchlist
Price: 14 CAD -0.85%
Market Cap: 53.5m CAD

Relative Value

There is not enough data to reliably calculate the relative value of QNTM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

QNTM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-66.7
Industry
21.7
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-101.8
Industry
16.6
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-98.3
Industry
22.5
vs History
73
vs Industry
Median 3Y
15.5
Median 5Y
52
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-74.2
Industry
13.1
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-69.5
Industry
16.6
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-100.9
Industry
15.8
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-100.9
Industry
19.1
vs History
74
vs Industry
Median 3Y
5
Median 5Y
104.1
Industry
1.9

Multiples Across Competitors

QNTM Competitors Multiples
Quantum BioPharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Quantum BioPharma Ltd
CNSX:QNTM
48.6m CAD 0 -1.3 -2 -1.9
US
Eli Lilly and Co
NYSE:LLY
939.9B USD 16.1 51.9 34.8 37.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.5B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
252.8B CHF 4.1 26.9 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 4.9 30.1 108.3 158.5
CH
Novartis AG
SIX:NOVN
206B CHF 4.6 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
239.1B USD 3.8 12.9 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 8.9 10.3
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
CA
Q
Quantum BioPharma Ltd
CNSX:QNTM
Average P/E: 23.3
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.9
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Q
Quantum BioPharma Ltd
CNSX:QNTM
Average EV/EBITDA: 437.5
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.4
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Q
Quantum BioPharma Ltd
CNSX:QNTM
Average EV/EBIT: 1 878.4
Negative Multiple: -1.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3